{"id":80658,"topic":"peptides","source":"webull.com","title":"FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds - webull.com","url":"https://www.webull.com/news/15544185062810624","url_hash":"f2f2c21260cb46f6950c76981796d43257e1abd2","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiWEFVX3lxTE4wRUxPckExclJsbnJIcVlUb3M2QlkzaDZJbzU3d0lyZWdPeWJnMHZuU216eWRkdXlxdEo0enh2SThKc0EzZC10Ul9BXzM0ZFc3VXVHZUNxOHA?oc=5\" target=\"_blank\">FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">webull.com</font>","content":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope.\nSCOTTSDALE, Ariz., Sept. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157. According to client-supplied records and Promise's current regulatory article, committee members voted 8-6-1 to recommend adding both BPC-157 free base and BPC-157 acetate to the Section 503A Bulks List.\nThe recommendation is advisory, not final FDA action. Rulemaking remains pending, and BPC-157 is not FDA-approved. Promise's analysis finds that this distinction is central for patients trying to understand what the committee vote changed and what it did not. That distinction matters when patients encounter headlines about the committee vote.\nThe advisory vote did not approve BPC-157\nFDA materials confirm that the committee considered BPC-157 free base and acetate during its July 23, 2026 meeting. FDA also states more broadly that advisory committee recommendations are non-binding.\nFDA review staff had proposed that neither form be added to the 503A Bulks List. The favorable committee recommendation reflects disagreement between advisory members and FDA staff rather than an FDA endorsement.\nFDA's BPC-157 briefing document also states that neither form has an applicable USP/NF drug-substance monograph and neither is a component of an FDA-approved drug. Inclusion on a compounding bulks list, if ultimately completed through rulemaking, would still not make a compounded preparation FDA-approved.\nHuman evidence remains limited\nThe regulatory discussion also comes against a limited human evidence base. A 2025 systematic review in HSS Journal identified 36 studies that met its inclusion criteria. Of those, 35 were preclinical and one was clinical. The review reported that it found no clinical safety data.\nThat imbalance matters because findings from laboratory or animal studies should not be translated into claims about human treatment outcomes. The available research can describe what has been studied, but it does not justify promises about safety, efficacy, healing, or recovery.\nFor patients, that means the committee vote should be understood as part of a regulatory process rather than as confirmation of clinical benefit.\nPrescription access remains clinician-gated\nPromise operates a doctor-guided telehealth platform in which treatment requests begin with an online medical evaluation. A licensed physician reviews the information and decides whether a prescription is appropriate.\nIf prescribed, the preparation is compounded and dispensed by a licensed U.S. pharmacy. The company says nothing is sold without provider review. That process is operational context, not evidence that BPC-157 is safe or effective, and provider approval is not automatic.\nMethodology\nPromise synthesized FDA materials from the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA's BPC-157 briefing document, FDA guidance on compounded drugs, a 2025 peer-reviewed systematic review, and client-supplied operational information. No proprietary patient-outcome survey or efficacy dataset was used.\nFrequently Asked Questions\nThe following questions address the regulatory status of BPC-157, the evidence base, and how clinician-guided access works.\nWhat did the July 2026 advisory vote change?\nThe committee recommended adding BPC-157 free base and acetate to the Section 503A Bulks List. The recommendation is non-binding and did not itself complete FDA rulemaking.\nIs BPC-157 FDA-approved?\nBPC-157 is not FDA-approved, and compounded preparations are not FDA-approved drugs. The advisory vote did not change that status.\nHow much human evidence is available?\nThe 2025 systematic review included 36 studies, with 35 preclinical studies and one clinical study. It reported finding no clinical safety data.\nHow is BPC-157 prescribed through Promise?\nThe process begins with an online medical evaluation. A licensed physician determines whether prescribing is appropriate, and a licensed pharmacy compounds and dispenses the preparation if a prescription is issued.\nAbout Promise\nPromise is a doctor-guided telehealth platform founded in 2026 and based in Scottsdale, Arizona. It provides access to peptide therapy, weight management, and hormone care through licensed-provider review. BPC-157 is one of the compounded peptide programs offered through the platform.\nMedia Contact\nContact: Max Power\nEmail: stacey@mypromise.com\n    Location: Scottsdale, AZ\nView original content to download multimedia:https://www.prnewswire.com/news-releases/fda-advisory-panel-backs-bpc-157-for-503a-bulks-list-in-8-6-1-vote-promise-analysis-finds-302872695.html\nSOURCE Promise (mypromise.com)","image_url":null,"lang":"en","published_at":"2026-09-09T22:54:21+00:00","fetched_at":"2026-09-12T07:15:09+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157.","cluster_id":3476683,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.webull.com/news/15544185062810624","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4892 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4892,"summary_length":369,"usable_text_length":4892,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4892,"summary_length":369}},"news_item":{"id":80658,"canonical_url":"https://www.webull.com/news/15544185062810624","source_url":"https://www.webull.com/news/15544185062810624","title":"FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds - webull.com","source_name":"webull.com","author":null,"published_at":"2026-09-09T22:54:21+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiWEFVX3lxTE4wRUxPckExclJsbnJIcVlUb3M2QlkzaDZJbzU3d0lyZWdPeWJnMHZuU216eWRkdXlxdEo0enh2SThKc0EzZC10Ul9BXzM0ZFc3VXVHZUNxOHA?oc=5\" target=\"_blank\">FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">webull.com</font>","full_text":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope.\nSCOTTSDALE, Ariz., Sept. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157. According to client-supplied records and Promise's current regulatory article, committee members voted 8-6-1 to recommend adding both BPC-157 free base and BPC-157 acetate to the Section 503A Bulks List.\nThe recommendation is advisory, not final FDA action. Rulemaking remains pending, and BPC-157 is not FDA-approved. Promise's analysis finds that this distinction is central for patients trying to understand what the committee vote changed and what it did not. That distinction matters when patients encounter headlines about the committee vote.\nThe advisory vote did not approve BPC-157\nFDA materials confirm that the committee considered BPC-157 free base and acetate during its July 23, 2026 meeting. FDA also states more broadly that advisory committee recommendations are non-binding.\nFDA review staff had proposed that neither form be added to the 503A Bulks List. The favorable committee recommendation reflects disagreement between advisory members and FDA staff rather than an FDA endorsement.\nFDA's BPC-157 briefing document also states that neither form has an applicable USP/NF drug-substance monograph and neither is a component of an FDA-approved drug. Inclusion on a compounding bulks list, if ultimately completed through rulemaking, would still not make a compounded preparation FDA-approved.\nHuman evidence remains limited\nThe regulatory discussion also comes against a limited human evidence base. A 2025 systematic review in HSS Journal identified 36 studies that met its inclusion criteria. Of those, 35 were preclinical and one was clinical. The review reported that it found no clinical safety data.\nThat imbalance matters because findings from laboratory or animal studies should not be translated into claims about human treatment outcomes. The available research can describe what has been studied, but it does not justify promises about safety, efficacy, healing, or recovery.\nFor patients, that means the committee vote should be understood as part of a regulatory process rather than as confirmation of clinical benefit.\nPrescription access remains clinician-gated\nPromise operates a doctor-guided telehealth platform in which treatment requests begin with an online medical evaluation. A licensed physician reviews the information and decides whether a prescription is appropriate.\nIf prescribed, the preparation is compounded and dispensed by a licensed U.S. pharmacy. The company says nothing is sold without provider review. That process is operational context, not evidence that BPC-157 is safe or effective, and provider approval is not automatic.\nMethodology\nPromise synthesized FDA materials from the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA's BPC-157 briefing document, FDA guidance on compounded drugs, a 2025 peer-reviewed systematic review, and client-supplied operational information. No proprietary patient-outcome survey or efficacy dataset was used.\nFrequently Asked Questions\nThe following questions address the regulatory status of BPC-157, the evidence base, and how clinician-guided access works.\nWhat did the July 2026 advisory vote change?\nThe committee recommended adding BPC-157 free base and acetate to the Section 503A Bulks List. The recommendation is non-binding and did not itself complete FDA rulemaking.\nIs BPC-157 FDA-approved?\nBPC-157 is not FDA-approved, and compounded preparations are not FDA-approved drugs. The advisory vote did not change that status.\nHow much human evidence is available?\nThe 2025 systematic review included 36 studies, with 35 preclinical studies and one clinical study. It reported finding no clinical safety data.\nHow is BPC-157 prescribed through Promise?\nThe process begins with an online medical evaluation. A licensed physician determines whether prescribing is appropriate, and a licensed pharmacy compounds and dispenses the preparation if a prescription is issued.\nAbout Promise\nPromise is a doctor-guided telehealth platform founded in 2026 and based in Scottsdale, Arizona. It provides access to peptide therapy, weight management, and hormone care through licensed-provider review. BPC-157 is one of the compounded peptide programs offered through the platform.\nMedia Contact\nContact: Max Power\nEmail: stacey@mypromise.com\n    Location: Scottsdale, AZ\nView original content to download multimedia:https://www.prnewswire.com/news-releases/fda-advisory-panel-backs-bpc-157-for-503a-bulks-list-in-8-6-1-vote-promise-analysis-finds-302872695.html\nSOURCE Promise (mypromise.com)","excerpt":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157.","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 4892 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.webull.com/news/15544185062810624","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4892 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4892,"summary_length":369,"usable_text_length":4892,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4892,"summary_length":369}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds - webull.com","url":"https://www.webull.com/news/15544185062810624","summary":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157.","source":"webull.com","date":"2026-09-09T22:54:21+00:00","content":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope.\nSCOTTSDALE, Ariz., Sept. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157. According to client-supplied records and Promise's current regulatory article, committee members voted 8-6-1 to recommend adding both BPC-157 free base and BPC-157 acetate to the Section 503A Bulks List.\nThe recommendation is advisory, not final FDA action. Rulemaking remains pending, and BPC-157 is not FDA-approved. Promise's analysis finds that this distinction is central for patients trying to understand what the committee vote changed and what it did not. That distinction matters when patients encounter headlines about the committee vote.\nThe advisory vote did not approve BPC-157\nFDA materials confirm that the committee considered BPC-157 free base and acetate during its July 23, 2026 meeting. FDA also states more broadly that advisory committee recommendations are non-binding.\nFDA review staff had proposed that neither form be added to the 503A Bulks List. The favorable committee recommendation reflects disagreement between advisory members and FDA staff rather than an FDA endorsement.\nFDA's BPC-157 briefing document also states that neither form has an applicable USP/NF drug-substance monograph and neither is a component of an FDA-approved drug. Inclusion on a compounding bulks list, if ultimately completed through rulemaking, would still not make a compounded preparation FDA-approved.\nHuman evidence remains limited\nThe regulatory discussion also comes against a limited human evidence base. A 2025 systematic review in HSS Journal identified 36 studies that met its inclusion criteria. Of those, 35 were preclinical and one was clinical. The review reported that it found no clinical safety data.\nThat imbalance matters because findings from laboratory or animal studies should not be translated into claims about human treatment outcomes. The available research can describe what has been studied, but it does not justify promises about safety, efficacy, healing, or recovery.\nFor patients, that means the committee vote should be understood as part of a regulatory process rather than as confirmation of clinical benefit.\nPrescription access remains clinician-gated\nPromise operates a doctor-guided telehealth platform in which treatment requests begin with an online medical evaluation. A licensed physician reviews the information and decides whether a prescription is appropriate.\nIf prescribed, the preparation is compounded and dispensed by a licensed U.S. pharmacy. The company says nothing is sold without provider review. That process is operational context, not evidence that BPC-157 is safe or effective, and provider approval is not automatic.\nMethodology\nPromise synthesized FDA materials from the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA's BPC-157 briefing document, FDA guidance on compounded drugs, a 2025 peer-reviewed systematic review, and client-supplied operational information. No proprietary patient-outcome survey or efficacy dataset was used.\nFrequently Asked Questions\nThe following questions address the regulatory status of BPC-157, the evidence base, and how clinician-guided access works.\nWhat did the July 2026 advisory vote change?\nThe committee recommended adding BPC-157 free base and acetate to the Section 503A Bulks List. The recommendation is non-binding and did not itself complete FDA rulemaking.\nIs BPC-157 FDA-approved?\nBPC-157 is not FDA-approved, and compounded preparations are not FDA-approved drugs. The advisory vote did not change that status.\nHow much human evidence is available?\nThe 2025 systematic review included 36 studies, with 35 preclinical studies and one clinical study. It reported finding no clinical safety data.\nHow is BPC-157 prescribed through Promise?\nThe process begins with an online medical evaluation. A licensed physician determines whether prescribing is appropriate, and a licensed pharmacy compounds and dispenses the preparation if a prescription is issued.\nAbout Promise\nPromise is a doctor-guided telehealth platform founded in 2026 and based in Scottsdale, Arizona. It provides access to peptide therapy, weight management, and hormone care through licensed-provider review. BPC-157 is one of the compounded peptide programs offered through the platform.\nMedia Contact\nContact: Max Power\nEmail: stacey@mypromise.com\n    Location: Scottsdale, AZ\nView original content to download multimedia:https://www.prnewswire.com/news-releases/fda-advisory-panel-backs-bpc-157-for-503a-bulks-list-in-8-6-1-vote-promise-analysis-finds-302872695.html\nSOURCE Promise (mypromise.com)","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.webull.com/news/15544185062810624","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 4892 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4892 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4892,"summary_length":369,"usable_text_length":4892,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4892,"summary_length":369}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/80658","export_markdown":"/api/items/80658/export?format=markdown","export_json":"/api/items/80658/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.webull.com/news/15544185062810624"},"formats":{"full":{"id":80658,"title":"FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds - webull.com","url":"https://www.webull.com/news/15544185062810624","source":"webull.com","author":null,"published_at":"2026-09-09T22:54:21+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157.","full_text":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope.\nSCOTTSDALE, Ariz., Sept. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157. According to client-supplied records and Promise's current regulatory article, committee members voted 8-6-1 to recommend adding both BPC-157 free base and BPC-157 acetate to the Section 503A Bulks List.\nThe recommendation is advisory, not final FDA action. Rulemaking remains pending, and BPC-157 is not FDA-approved. Promise's analysis finds that this distinction is central for patients trying to understand what the committee vote changed and what it did not. That distinction matters when patients encounter headlines about the committee vote.\nThe advisory vote did not approve BPC-157\nFDA materials confirm that the committee considered BPC-157 free base and acetate during its July 23, 2026 meeting. FDA also states more broadly that advisory committee recommendations are non-binding.\nFDA review staff had proposed that neither form be added to the 503A Bulks List. The favorable committee recommendation reflects disagreement between advisory members and FDA staff rather than an FDA endorsement.\nFDA's BPC-157 briefing document also states that neither form has an applicable USP/NF drug-substance monograph and neither is a component of an FDA-approved drug. Inclusion on a compounding bulks list, if ultimately completed through rulemaking, would still not make a compounded preparation FDA-approved.\nHuman evidence remains limited\nThe regulatory discussion also comes against a limited human evidence base. A 2025 systematic review in HSS Journal identified 36 studies that met its inclusion criteria. Of those, 35 were preclinical and one was clinical. The review reported that it found no clinical safety data.\nThat imbalance matters because findings from laboratory or animal studies should not be translated into claims about human treatment outcomes. The available research can describe what has been studied, but it does not justify promises about safety, efficacy, healing, or recovery.\nFor patients, that means the committee vote should be understood as part of a regulatory process rather than as confirmation of clinical benefit.\nPrescription access remains clinician-gated\nPromise operates a doctor-guided telehealth platform in which treatment requests begin with an online medical evaluation. A licensed physician reviews the information and decides whether a prescription is appropriate.\nIf prescribed, the preparation is compounded and dispensed by a licensed U.S. pharmacy. The company says nothing is sold without provider review. That process is operational context, not evidence that BPC-157 is safe or effective, and provider approval is not automatic.\nMethodology\nPromise synthesized FDA materials from the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA's BPC-157 briefing document, FDA guidance on compounded drugs, a 2025 peer-reviewed systematic review, and client-supplied operational information. No proprietary patient-outcome survey or efficacy dataset was used.\nFrequently Asked Questions\nThe following questions address the regulatory status of BPC-157, the evidence base, and how clinician-guided access works.\nWhat did the July 2026 advisory vote change?\nThe committee recommended adding BPC-157 free base and acetate to the Section 503A Bulks List. The recommendation is non-binding and did not itself complete FDA rulemaking.\nIs BPC-157 FDA-approved?\nBPC-157 is not FDA-approved, and compounded preparations are not FDA-approved drugs. The advisory vote did not change that status.\nHow much human evidence is available?\nThe 2025 systematic review included 36 studies, with 35 preclinical studies and one clinical study. It reported finding no clinical safety data.\nHow is BPC-157 prescribed through Promise?\nThe process begins with an online medical evaluation. A licensed physician determines whether prescribing is appropriate, and a licensed pharmacy compounds and dispenses the preparation if a prescription is issued.\nAbout Promise\nPromise is a doctor-guided telehealth platform founded in 2026 and based in Scottsdale, Arizona. It provides access to peptide therapy, weight management, and hormone care through licensed-provider review. BPC-157 is one of the compounded peptide programs offered through the platform.\nMedia Contact\nContact: Max Power\nEmail: stacey@mypromise.com\n    Location: Scottsdale, AZ\nView original content to download multimedia:https://www.prnewswire.com/news-releases/fda-advisory-panel-backs-bpc-157-for-503a-bulks-list-in-8-6-1-vote-promise-analysis-finds-302872695.html\nSOURCE Promise (mypromise.com)","reading_time_min":3,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 4892 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.webull.com/news/15544185062810624","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4892 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4892,"summary_length":369,"usable_text_length":4892,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4892,"summary_length":369}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4892 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4892,"summary_length":369,"usable_text_length":4892,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4892,"summary_length":369}},"actions":{"read":"/item/80658","export_markdown":"/api/items/80658/export?format=markdown","export_json":"/api/items/80658/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.webull.com/news/15544185062810624"}},"digest":{"id":80658,"title":"FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds - webull.com","url":"https://www.webull.com/news/15544185062810624","source":"webull.com","topic":"peptides","published_at":"2026-09-09T22:54:21+00:00","excerpt":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 4892 characters.","reading_time_min":3,"cluster_id":3476683},"card":{"display_title":"FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds - webull.com","subtitle":"webull.com · 2026-09-09","summary":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope. 8,…","badges":["quality:high"],"links":{"read":"/item/80658","original":"https://www.webull.com/news/15544185062810624","diagnose":"/api/diagnose?url=https%3A//www.webull.com/news/15544185062810624"},"quality_warning":null},"export":{"title":"FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds - webull.com","url":"https://www.webull.com/news/15544185062810624","summary":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157.","source":"webull.com","date":"2026-09-09T22:54:21+00:00","content":"The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope.\nSCOTTSDALE, Ariz., Sept. 8, 2026 /PRNewswire/ -- A July 2026 vote by the FDA Pharmacy Compounding Advisory Committee has put renewed attention on the regulatory status of BPC-157. According to client-supplied records and Promise's current regulatory article, committee members voted 8-6-1 to recommend adding both BPC-157 free base and BPC-157 acetate to the Section 503A Bulks List.\nThe recommendation is advisory, not final FDA action. Rulemaking remains pending, and BPC-157 is not FDA-approved. Promise's analysis finds that this distinction is central for patients trying to understand what the committee vote changed and what it did not. That distinction matters when patients encounter headlines about the committee vote.\nThe advisory vote did not approve BPC-157\nFDA materials confirm that the committee considered BPC-157 free base and acetate during its July 23, 2026 meeting. FDA also states more broadly that advisory committee recommendations are non-binding.\nFDA review staff had proposed that neither form be added to the 503A Bulks List. The favorable committee recommendation reflects disagreement between advisory members and FDA staff rather than an FDA endorsement.\nFDA's BPC-157 briefing document also states that neither form has an applicable USP/NF drug-substance monograph and neither is a component of an FDA-approved drug. Inclusion on a compounding bulks list, if ultimately completed through rulemaking, would still not make a compounded preparation FDA-approved.\nHuman evidence remains limited\nThe regulatory discussion also comes against a limited human evidence base. A 2025 systematic review in HSS Journal identified 36 studies that met its inclusion criteria. Of those, 35 were preclinical and one was clinical. The review reported that it found no clinical safety data.\nThat imbalance matters because findings from laboratory or animal studies should not be translated into claims about human treatment outcomes. The available research can describe what has been studied, but it does not justify promises about safety, efficacy, healing, or recovery.\nFor patients, that means the committee vote should be understood as part of a regulatory process rather than as confirmation of clinical benefit.\nPrescription access remains clinician-gated\nPromise operates a doctor-guided telehealth platform in which treatment requests begin with an online medical evaluation. A licensed physician reviews the information and decides whether a prescription is appropriate.\nIf prescribed, the preparation is compounded and dispensed by a licensed U.S. pharmacy. The company says nothing is sold without provider review. That process is operational context, not evidence that BPC-157 is safe or effective, and provider approval is not automatic.\nMethodology\nPromise synthesized FDA materials from the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA's BPC-157 briefing document, FDA guidance on compounded drugs, a 2025 peer-reviewed systematic review, and client-supplied operational information. No proprietary patient-outcome survey or efficacy dataset was used.\nFrequently Asked Questions\nThe following questions address the regulatory status of BPC-157, the evidence base, and how clinician-guided access works.\nWhat did the July 2026 advisory vote change?\nThe committee recommended adding BPC-157 free base and acetate to the Section 503A Bulks List. The recommendation is non-binding and did not itself complete FDA rulemaking.\nIs BPC-157 FDA-approved?\nBPC-157 is not FDA-approved, and compounded preparations are not FDA-approved drugs. The advisory vote did not change that status.\nHow much human evidence is available?\nThe 2025 systematic review included 36 studies, with 35 preclinical studies and one clinical study. It reported finding no clinical safety data.\nHow is BPC-157 prescribed through Promise?\nThe process begins with an online medical evaluation. A licensed physician determines whether prescribing is appropriate, and a licensed pharmacy compounds and dispenses the preparation if a prescription is issued.\nAbout Promise\nPromise is a doctor-guided telehealth platform founded in 2026 and based in Scottsdale, Arizona. It provides access to peptide therapy, weight management, and hormone care through licensed-provider review. BPC-157 is one of the compounded peptide programs offered through the platform.\nMedia Contact\nContact: Max Power\nEmail: stacey@mypromise.com\n    Location: Scottsdale, AZ\nView original content to download multimedia:https://www.prnewswire.com/news-releases/fda-advisory-panel-backs-bpc-157-for-503a-bulks-list-in-8-6-1-vote-promise-analysis-finds-302872695.html\nSOURCE Promise (mypromise.com)","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.webull.com/news/15544185062810624","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 4892 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4892 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4892,"summary_length":369,"usable_text_length":4892,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4892,"summary_length":369}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}